Gerard A. Wills

Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG

Ngen, Inc. advanced diagnostics provides physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. The company is headquartered in San Diego, CA